Get the one approved appetite drug licensed beyond a single country
A drug that improves appetite and lean weight in cancer wasting is approved in Japan but almost nowhere else. Reviewing the existing evidence could widen access quickly.
Anamorelin, a ghrelin receptor agonist, is approved in Japan for cancer cachexia in several tumour types, having shown gains in lean body mass with inconsistent effects on handgrip strength in the ROMANA programme. Other regulators declined largely on the function endpoint. A reappraisal using pooled data with a qualified function endpoint, or a confirmatory pragmatic trial in a stratified population, could resolve the question.
- Cachexia, toxicity and the limits of the patient · Patients often die of wasting or cannot tolerate the doses that would work. Treating the patient, not just the tumour, lags far behind.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaTreat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles
Shares Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Gastric & gastro-oesophageal junction cancer.
- IdeaQualify a physical function endpoint so anti-wasting drugs can be approved
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology.
- TechnologyCachexia-directed therapy (GDF-15 blockade)
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Exercise & lifestyle oncology, Pancreatic ductal adenocarcinoma.
- IdeaCatch wasting early with a smart scale and a step counter
Shares Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- IdeaA cheap old tablet to restore appetite
Shares Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Most of the world has almost no cancer care, Gastric & gastro-oesophageal junction cancer.
- PathwayCancer cachexia
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Exercise & lifestyle oncology, Gastric & gastro-oesophageal junction cancer.
- IdeaConfirm low-dose olanzapine for appetite and weight in advanced cancer worldwide
Shares Cachexia, toxicity and the limits of the patient, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer.
- TechnologyResistance training and protein for cachexia and sarcopenia
Shares Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient, Exercise & lifestyle oncology, Gastric & gastro-oesophageal junction cancer.